Table 3 Differences in cardiometabolic health risk indicators across gender and antipsychotic treatment groups

Gender

1.21

[0.46, 2.88]

1.44

.154

3.25

[-1.84, 8.34]

1.27

.208

46.24 (male)

−2.22

.027*

44.76 (male)

−1.15

.130

49.32 (male)

−3.62

< .001***

34.45 (female)

36.67 (female)

29.89 (female)

Clozapine prescribed

(yes Vs no)

0.85

[-1.41, 3.11]

0.75

.456

3.07

[-3.60, 9.74]

0.92

.363

41.52 (no)

−0.02

.985

56.04 (yes)

−2.52

.012*

55.71 (yes)

−2.45

.014*

41.39 (yes)

38.51 (no)

8.57 (no)

Oral and LAI

(combination Vs single route)

2.58

[0.71, 4.46]

2.74

.008**

4.30

[-1.60, 10.20]

1.45

.151

50.82 (combine)

−1.96

.050

42.46 (single)

−0.67

.505

53.68 (combine)

−2.54

.011*

38.69 (single)

38.32 (combined)

37.83 (single)

1^st and 2^nd generation antipsychotics (combination Vs single class)

3.01

[0.77, 5.25]

2.67

.009**

2.98

[-4.13, 10.9]

0.83

.407

49.54 (combine)

−1.28

.202

42.20 (single)

−0.65

.519

59.50 (combine)

−2.83

.005**

40.12 (single)

37.42 (combine)

38.41 (single)

MD^c

[95% CI]

F

p

MD^c

[95% CI]

F

p

MR^d

H

p

MR^d

H

p

MR^d

H

p

Number of antipsychotic types

(one, two, three)

5.25

[0.73, 9.77]

4.93

.010*

5.43

[-9.13, 19.98]

0.47

1.000

49.44 (two)

3.83

.147

43.45 (one)

1.14

.564

37.19 (one)

6.71

.035*

38.50 (three)

38.23 (two)

47.52 (two)

38.19 (one)

34.75 (three)

63.50 (three)

Dosage of prescribed antipsychotics

(>2 DDD, 1.1–2 DDD, ≤1 DDD)

3.94

[1.57, 6.30]

8.73

.001***

9.73

[2.22, 17.24]

5.28

.007**

49.90 (>2)

7.77

.021*

42.66 (≤1)

0.13

.940

52.04 (>2)

9.41

.009**

44.44 (1.1–2)

40.81 (>2)

42.90 (1.1–2)

2.79

[0.52, 5.06]

8.73

.011*

32.81 (≤1)

40.71 (1.1–2)

32.45 (≤1)